Refining pathological evaluation of neoadjuvant therapy for adenocarcinoma of the esophagus
Refining pathological evaluation of neoadjuvant therapy for adenocarcinoma of the esophagus
复制标题
DOI：
10.3748/wjg.v19.i48.9282
复制
发表时间：
2013-12-28
影响因子：
4.3
通讯作者：
Bateman, Andrew R.
中科院分区：
文献类型：
--
作者：
Noble, Fergus;Nolan, Luke;Bateman, Andrew R.
目的：为了评估肿瘤消退等级（TRG）和淋巴结分期下降，以帮助确定患者谁受益于新辅助chemotherapy.METHODS：2005年至2011年期间，在一个单一的机构，218例食管腺癌或食管胃交界处单独手术或新辅助化疗和手术治疗进行了审查。对于可手术患者，考虑了由铂、氟嘧啶和蒽环类药物组成的三联新辅助化疗（世界卫生组织体能状态
AIM: To assess tumour regression grade (TRG) and lymph node downstaging to help define patients who benefit from neoadjuvant chemotherapy.METHODS: Two hundred and eighteen consecutive patients with adenocarcinoma of the esophagus or gas-tro-esophageal junction treated with surgery alone or neoadjuvant chemotherapy and surgery between 2005 and 2011 at a single institution were reviewed. Triplet neoadjuvant chemotherapy consisting of platinum, fluoropyrimidine and anthracycline was considered for operable patients (World Health Organization performance status